The overall objective of this contract is to demonstrate the versatility and efficacy of our programmable antiviral technology platform by assembling the preclinical package for LNA14, performing a…
Active Definitive Contract Awarded Last action
- Contract number
- 75A50124C00052
- Awardee
-
4J Therapeutics Inc. UEI SZCGV7LQJKR4
- Awarding agency
-
Office of the Assistant Secretary for Preparedness and Response
Department of Health and Human Services
- Obligated
- $63,083,814
Award facts
- Opportunity
-
- Biomedical Advanced Research and Development Authority (BARDA) Broad Agency Announcement (BAA) Solicitation · BAA23100SOL00004 · Posted Sep 26, 2023
- Contract value 17% obligated
-
- $63,083,814.00 Current, with exercised options
- $362,232,711.00 Potential, with all options
- Completion date 27% complete
-
- Current, with exercised options
- Potential, with all options
- Contracting staff
- NAICS code
- 541714 Research and Development in Biotechnology (except Nanobiotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 1 offer Negotiated Proposal / Quote
- Pricing
- Cost Plus Fixed Fee
- Place of performance
- Palo Alto, CA 94304, USA
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Exercise an Option | $10,599,454 | |
| Exercise an Option | $14,894,558 | |
| Other Administrative Action | $3 | |
| Other Administrative Action | $0 | |
| Exercise an Option | $16,992,129 | |
| Original award | $20,597,670 |
About this award
The Department of Health and Human Services, Office of the Assistant Secretary for Preparedness and Response (BARDA), awarded a definitive cost-plus-fixed-fee contract to 4J Therapeutics Inc. with a ceiling value of $362.2 million on September 30, 2024, to demonstrate the versatility and efficacy of a programmable antiviral technology platform by assembling the preclinical package for LNA14 and performing a Phase 1A study in healthy adult human subjects.
This modification exercises CLIN 4/Option 3 and updates estimated cost-plus-fixed-fee CLINs and the Statement of Work. The contract was originated under BARDA's broad solicitation for advanced research and development of medical countermeasures against chemical, biological, radiological, and nuclear (CBRN) threats, pandemic influenza, and emerging infectious diseases. Work is performed in Palo Alto, California. Period of performance extends through June 30, 2032. The solicitation operates on a three-stage process with a final proposal submission deadline of September 25, 2028, and contemplates multiple awards of various values and contract types across twelve areas of interest, with evaluation based on program relevance, scientific and technical merit, offeror capabilities, cost realism, and past performance.
Description
The overall objective of this contract is to demonstrate the versatility and efficacy of our programmable antiviral technology platform by assembling the preclinical package for LNA14, performing a phase 1A study in healthy adult human subjects, and
Quick answers
Who was awarded contract 75A50124C00052?
75A50124C00052 was awarded to 4J Therapeutics Inc. by Office of the Assistant Secretary for Preparedness and Response (Department of Health and Human Services) on September 30, 2024.
How much is contract 75A50124C00052 worth?
The government has obligated $63,083,814 on 75A50124C00052. Its potential value, with all options, is $362,232,711.
Was contract 75A50124C00052 competed?
The extent of competition for 75A50124C00052 was full and open competition. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award